<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9435">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05697835</url>
  </required_header>
  <id_info>
    <org_study_id>202301070</org_study_id>
    <secondary_id>P50MH122351</secondary_id>
    <nct_id>NCT05697835</nct_id>
  </id_info>
  <brief_title>Perioperative Mental Health in Orthopedic Surgery</brief_title>
  <acronym>CPMH</acronym>
  <official_title>Behavioral Activation and Medication Optimization for Perioperative Mental Health in Orthopedic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Hybrid 1 Study will test the effectiveness of a bundled intervention comprised of&#xD;
      behavioral activation and medication optimization in reducing symptoms of depression and&#xD;
      anxiety in older adults undergoing Orthopedic surgery (compared with usual care), while&#xD;
      examining implementation outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2023</start_date>
  <completion_date type="Anticipated">February 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Hybrid Type 1 effectiveness-implementation randomized controlled trial design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Study staff responsible for administering ratings and collecting outcomes throughout the study are blinded. The investigator(s) are also blinded. This blinding is kept throughout the study until data collection is complete. At the end of the follow-up, the study coordinator will complete a blinding question to try to guess the arm to which each participant was allocated.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PHQ-ADS</measure>
    <time_frame>3 months post-operatively</time_frame>
    <description>PHQ-ADS (Patient Health Questionnaire Anxiety and Depression Scale) scores will be compared between the two study arms 3 months after surgery.&#xD;
PHQ-ADS is a composite measure of anxiety and depression. PHQ-ADS scores can range from 0 to 48 (with higher scores indicating more severe depression/anxiety)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Orthopedic Surgery</condition>
  <condition>Older Adults</condition>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Behavioral activation and medication optimization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference &amp; health condition.&#xD;
Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (treatment as usual)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral activation</intervention_name>
    <description>The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values</description>
    <arm_group_label>Behavioral activation and medication optimization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medication optimzation</intervention_name>
    <description>Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.</description>
    <arm_group_label>Behavioral activation and medication optimization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Care as usual</intervention_name>
    <description>Care as usual, with written resources provided</description>
    <arm_group_label>Control (treatment as usual)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adults ≥ 60 years&#xD;
&#xD;
          -  Scheduled primary hip or primary knee arthroplasty procedure&#xD;
&#xD;
          -  PHQ-ADS ≥ 10, indicating clinically significant depression or anxiety symptoms&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Barrier to communication (Unable to read, speak, and understand English)&#xD;
&#xD;
          -  Severe cognitive impairment screened by the SBT (Short Blessed Test) &gt;10&#xD;
&#xD;
          -  Acutely suicidal&#xD;
&#xD;
          -  Previous participation in this study or another CPMH study of the intervention bundle&#xD;
             or its feasibility.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Calfee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theresa Cordner, BS</last_name>
    <phone>314-273-7921</phone>
    <email>cordnert@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caitlin Bess</last_name>
    <phone>314-362-3561</phone>
    <email>caitlin.christy@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Cordner, BS</last_name>
      <phone>314-273-7921</phone>
      <email>cordnert@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Bess</last_name>
      <phone>314-286-0026</phone>
      <email>caitlin.christy@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ryan Calfee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Haroutounian, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael S Avidan, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Freedland, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Lenze, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Abraham, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Holzer, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Kannampallil, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>J. Phillip Miller, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Baumann, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bethany Pennington,, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kimberly Bartosiak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Politi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 14, 2023</study_first_submitted>
  <study_first_submitted_qc>January 14, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>May 5, 2023</last_update_submitted>
  <last_update_submitted_qc>May 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ryan Calfee, MD</investigator_full_name>
    <investigator_title>Professor of Orthopaedic Surgery</investigator_title>
  </responsible_party>
  <keyword>Behavioral: Behavioral activation</keyword>
  <keyword>Medication optimization</keyword>
  <keyword>Care as usual</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

